Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

Ken Ho (1) , Maria Fleseriu (2) , Ursula Kaiser (3) , Roberto Salvatori (4) , Thierry Brue (5, 6, 7) , M Beatriz Beatriz Lopes (8) , Pamela Kunz (9) , Mark Molitch (10) , Sally A Camper (11) , Mônica Gadelha (12) , Luis V Syro (13) , Edward Laws (3) , Martin Reincke (14) , Hiroshi Nishioka (15) , Ashley Grossman (16) , Ariel Barkan (11) , Felipe Casanueva (17) , John Wass (18) , Adam Mamelak (19) , Laurence Katznelson (20) , Aart J van Der Lely (21) , Sally Radovick (22) , Martin Bidlingmaier (14) , Margaret Boguszewski (23) , Jens Bollerslev (24) , Andrew Hoffman (25) , Nelson Oyesiku (26) , Gerald Raverot (27) , Anat Ben-Shlomo (19) , Rob Fowkes (28) , Ilan Shimon (29) , Hidenori Fukuoka (30) , Alberto Pereira (31) , Yona Greenman (32) , Anthony Heaney (33) , Mark Gurnell (34) , Gudmundur Johannsson (35) , Robert Osamura (36) , Michael Buchfelder (37) , Maria Chiara Zatelli (38) , Marta Korbonits (39) , Philippe Chanson (40) , Nienke Biermasz (31) , David Clemmons (41) , Niki Karavitaki (42) , Marcello Bronstein (43) , Peter Trainer (44) , Shlomo Melmed (19)

1 Garvan Institute of medical research
2 Oregon Health & Science University
3 BWH - Brigham & Women’s Hospital [Boston]
4 JHU - Johns Hopkins University
5 MMG - Marseille medical genetics - Centre de génétique médicale de Marseille
6 MarMaRa - Institut Marseille Maladies Rares
7 Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM]
8 University of Virginia
9 YSM - Yale School of Medicine [New Haven, Connecticut]
10 Northwestern University [Evanston]
11 University of Michigan [Ann Arbor]
12 UNIRIO - Universidade Federal do Estado do Rio de Janeiro
13 Hospital Pablo Tobón Uribe [Medellín, Colombie]
14 LMU - Ludwig-Maximilians-Universität München
15 Toranomon Hospital [Tokyo, Japan]
16 University of Oxford
17 USC - Universidade de Santiago de Compostela [Spain]
18 Churchill Hospital [Breast Care Unit]
19 Cedars-Sinai Medical Center
20 Stanford University
21 Erasmus MC - Erasmus University Medical Center [Rotterdam]
22 Rutgers-New Brunswick - Rutgers Robert Wood Johnson Medical School [New Brunswick, NJ, USA]
23 UTFPR - Federal University of Technology - Paraná
24 UiO - University of Oslo
25 Stanford University School of Medicine [CA, USA]
26 Emory University School of Medicine
27 HCL - Hospices Civils de Lyon
28 University of London [London]
29 Beilinson Hospital
30 Kobe University Hospital
31 Leiden University Medical Center (LUMC)
32 Tel Aviv Sourasky Medical Center [Te Aviv]
33 UCLA - University of California [Los Angeles]
34 CAM - University of Cambridge [UK]
35 GU - University of Gothenburg
36 Keio University School of Medicine [Tokyo, Japan]
37 University Hospital Erlangen = Uniklinikum Erlangen
38 UniFE - Università degli Studi di Ferrara = University of Ferrara
39 QMUL - Queen Mary University of London
40 Université Paris-Saclay
41 University of North Carolina at Chapel Hill School of Medicine
42 University of Birmingham [Birmingham]
43 Universidade Federal de São Paulo
44 University of Manchester [Manchester]

Abstract The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written précis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges.

Keywords: Pituitary neoplasm; pituitary adenoma; tumor; neuroendocrine

Domains: Life Sciences [q-bio]; Human health and pathology

Ken Ho, Maria Fleseriu, Ursula Kaiser, Roberto Salvatori, Thierry Brue, et al.. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5 (3), ⟨10.1210/jendso/bvaa205⟩. ⟨hal-03310331⟩